Peptide blend
KLOW
A pre-mixed vial of KPV, BPC-157, TB-500 and GHK-Cu. A search of PubMed on 15 November 2026 for KLOW with peptide, blend or BPC-157 in the title or summary text returned 0 records.
KLOW after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.
Drawn from the half-life in the app's model, ~3 h. The model's figures
- Compound
- KLOW
- Symbol
- KLW
- Family
- Healing peptides
- Parts
- 14
- References
- 24
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

9%The 7th most tracked compound in Milligram: of people who track compounds in Milligram logged KLOW in the last 90 days.
Schedule
Logged doses
Half of people logged between 2 and 5 mg per dose; the median was 4 mg.
Tracked alongside
The share of people logging KLOW who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
KLOW, also listed as KLOW blend, is a pre-mixed vial of four peptides: KPV 10 mg, BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg, 80 mg in total. The components are lysine-proline-valine (KPV), body protection compound 157 (BPC-157), thymosin beta-4 fragment (TB-500) and glycyl-L-histidyl-L-lysine copper (GHK-Cu).1,2 A search of PubMed on 15 November 2026 for KLOW with peptide, blend or BPC-157 in the title or summary text returned 0 records, and a search for KPV, BPC-157, TB-500 or thymosin, and GHK-Cu or GHK in the same record also returned 0 records. A 2026 scoping review that covered BPC-157, thymosin beta-4 or TB-500 and GHK-Cu among its peptides reported that 67% of identified publications used preclinical animal models.3 FDA briefing documents for its July 2026 compounding advisory committee state that KPV, BPC-157 and TB-500 are not components of an FDA-approved drug, and the KPV document says KPV is promoted as a compounded drug product in combination with BPC-157, TB-500, AOD9604 and Follistatin-344.4,5,6
GLOW is a three-peptide blend of BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg, which is KLOW without KPV, and BPC-157 + TB-500 is a two-peptide blend of BPC-157 10 mg and TB-500 10 mg.
How it works
KPV
KPV (Lys-Pro-Val) is a C-terminal peptide fragment of alpha-melanocyte stimulating hormone.7 In cell experiments with human intestinal epithelial cells and human T cells, nanomolar concentrations of KPV inhibited activation of NF-kappaB and MAP kinase inflammatory signalling pathways and reduced pro-inflammatory cytokine secretion, and the authors report that KPV acts via PepT1.1 FDA's briefing document states that the molecular targets underlying the pharmacological effects of KPV-related substances remain unknown, and that FDA has not identified any clinical studies or human exposure data for KPV via any route of administration.4
BPC-157
BPC-157 is a synthetic pentadecapeptide derived from a gastric protein fragment.8 A 2025 systematic review of 36 studies, 35 of them preclinical, states that the studies suggest BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines.9 FDA's briefing document states that the molecular targets for BPC-157 have not been identified and its mechanisms of action remain poorly understood.5
TB-500
TB-500 is described in FDA's briefing document as a synthetic N-acetylated heptapeptide containing amino acids 17 through 23 (LKKTETQ) of the full-length, 43-amino-acid peptide thymosin beta-4.6 A 2026 orthopaedic review says TB-500 is frequently conflated with full-length thymosin beta-4 despite the absence of validated biologic or clinical equivalence.10 FDA's document says the segment LKKTET is known as the actin-binding region of thymosin beta-4, and it has been hypothesised that LKKTETQ may share thymosin beta-4's G-actin buffering capacity.6 In a cell culture assay cited by FDA, wound closure with TB-500 at 50 µg/mL was not significantly different from vehicle.6
GHK-Cu
GHK-Cu is the copper-bound form of the human tripeptide glycyl-L-histidyl-L-lysine.11 A 2015 review states that GHK is present in human plasma, saliva and urine but declines with age, proposes that it functions as a complex with copper 2+ which accelerates wound healing and skin repair, and reports wound healing in dogs, rats, mice and pigs; its authors list Skin Biology as their affiliation.12
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~3 h
- Bioavailability
- 95%
- Typical dose
- 4–10 mg/day
- Route
- SubQ
The searches of PubMed on 15 November 2026 returned 0 records on the blend, so steady state and elimination of the blend are not described in them.
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~3 hours | No study measured this for the blend or for all four components. |
| Time to peak | ~0.5 hours | No study measured this for the blend or for all four components. |
| Bioavailability (SubQ) | ~95% | No study measured this for the blend or for all four components. |
| Half-life, BPC-157 alone13 | Under 30 minutes | Elimination half-life in rats and beagle dogs |
| Bioavailability, BPC-157 alone13 | About 14% to 19% (rats), 45% to 51% (beagle dogs) | Absolute bioavailability after intramuscular injection |
| Time to peak, TB-500 alone6 | 60 to 120 minutes | Plasma concentrations in horses after a 10 mg subcutaneous dose |
| Route | Subcutaneous | |
| Typical dose | 4 to 10 mg/day | The range is the app's figure; no study used the blend. |
| Vial contents | 80 mg: KPV 10, BPC-157 10, TB-500 10, GHK-Cu 50 | |
| Evidence level3 | Emerging | No study of the blend; a 2026 scoping review reported 67% of publications on BPC-157, TB-500 and GHK-Cu used animal models. |
By component
In rats and beagle dogs, BPC-157 showed linear pharmacokinetics, with urine and bile as the main excretory pathways.13 FDA reports no human pharmacokinetic data for BPC-157 after oral, subcutaneous, nasal or transdermal administration.5 In the horse study FDA describes, TB-500 plasma concentrations were unquantifiable between 6 and 10 hours after the dose, and FDA did not identify clinical studies in humans assessing its pharmacokinetics.6 After a single intravenous dose of GHK in rats, a plasma assay study reported that GHK was rapidly degraded to L-histidyl-L-lysine, which was eliminated rapidly.14 For KPV, FDA did not identify clinical studies in humans assessing pharmacokinetics by any route of administration.4
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| BPC-157, Lee and Padgett 202115,10 | Retrospective chart review at the Institute for Hormonal Balance in Orlando, Florida, with a telephone survey; described as uncontrolled in 2026 reviews | 17 patients; 16 reached by phone | Intra-articular knee injection of BPC 157 alone (12 patients) or with TB4 (4 patients); dose not stated in the PubMed record; most injections 6 months to 1 year before the study | 11 of 12 given BPC 157 alone reported significant improvement in knee pain; of the 4 given BPC 157 and TB4, 75% reported significant improvement and 25% no relief; no specific tools measured function or quality of life |
| BPC-157, Lee and colleagues 202416,8 | Pilot study in interstitial cystitis at a private clinic, described as uncontrolled in a 2026 review; BPC-157 from a 503A compounding pharmacy; Global Response Assessment questionnaire | 12 women aged 39 to 76, none of whom had responded to pentosan polysulfate | 10 mg in total, injected around the inflamed area of the bladder in a single procedure | Complete resolution of symptoms after one treatment in 10 of 12; the other 2 rated success at 80%; no adverse events reported |
| BPC-157, Lee and Burgess 202517 | IRB-approved pilot safety study at a private clinic in Florida | n = 2, each of whom had received intravenous BPC-157 before | 10 mg in 250 cc of normal saline over one hour on day 1, 20 mg on day 2 | No measurable effects on tested biomarkers of the heart, liver, kidneys, thyroid or blood glucose; no side effects reported |
| Thymosin beta-4 (FDA states it is not the same substance as TB-500), Ruff and colleagues 201018,6 | Randomised, placebo-controlled study of intravenous thymosin beta-4 in healthy volunteers | Four cohorts of 10 | Single intravenous dose of 42, 140, 420 or 1260 mg (as stated in the source), then the same dose daily for 14 days | Adverse events infrequent and mild or moderate; no dose limiting toxicities or serious adverse events |
| GHK-Cu, Miller and colleagues 200619 | Randomised study of topical skin care with or without GHK-Cu after CO2 laser resurfacing; blinded evaluators | 13 completed | Topical post-treatment regimens; assessed to 12 weeks | Questionnaire-reported improvement in overall skin quality was higher with GHK-Cu (P = .04); blinded evaluators found no statistically significant group difference in earlier resolution of erythema |
Sources in this part
- 4US Food and Drug Administration, 2026
- 5US Food and Drug Administration, 2026
- 6US Food and Drug Administration, 2026
- 8Mateescu et al., 2026
- 10Tham et al., 2026
- 11Najafi et al., 2026
- 15Lee et al., 2021
- 16Lee et al., 2024
- 17Lee et al., 2025
- 18Ruff et al., 2010
- 19Miller et al., 2006
- 20Poolton et al., 2026
- 21Biçer O, 2026
The three human studies of BPC-157 share a first author, Lee E, and were done at the Institute for Hormonal Balance in Orlando, Florida, and at private clinics.15,16,17 A 2026 systematic review of the three studies (30 people) judged them to be of poor methodological quality and rated the overall certainty of evidence as very low.20 In the 2021 study, 4 patients received a combination of BPC 157 and TB4, which FDA's BPC-157 briefing describes as a compounded combination of thymosin-beta-4 and BPC-157 used in patients with knee pain.15,5 FDA's KPV briefing reports no published studies in which compounded or non-compounded KPV was used in humans, and a 2026 orthopaedic review states that none of BPC-157, thymosin beta-4 or TB-500 has controlled human orthopaedic efficacy evidence.4,10 For GHK-Cu, a 2026 systematic review states that most randomized trials are small and were conducted on facial cosmetic creams.11
A 2026 rat study combined BPC-157 and TB-500
A 2026 exploratory study in 32 male Sprague-Dawley rats with a transected and repaired Achilles tendon, 8 per group, compared BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, the two together and a control, all given intraperitoneally for four weeks.21 Maximum load to failure was higher in the BPC-157 and TB-500 groups than in controls, reaching statistical significance in the TB-500 group (p < 0.05), and total Movin scores were significantly lower in the TB-500 and combined groups.21 The authors report that combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.21
Doses reported in studies
No dose from a study of the blend exists in the searches of PubMed on 15 November 2026, which returned 0 records, so the rows below are doses given in studies of single components.
| Source | Dose | Frequency | Length |
|---|---|---|---|
| BPC-157, intravesical (12 women)16 | 10 mg in total | Single procedure | One treatment |
| BPC-157, intravenous (2 people)17 | 10 mg on day 1 and 20 mg on day 2 | One infusion a day over one hour | Days 1 and 2 |
| Thymosin beta-4, intravenous (healthy volunteers; not TB-500)18 | 42, 140, 420 or 1260 mg (as stated in the source) | Single dose, then daily | 14 days |
| BPC-157 and TB-500, intraperitoneal (rats)21 | BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or both | Daily | Four weeks |
Sources in this part
Side effects reported
No trial of the blend reports side effects, since the searches of PubMed on 15 November 2026 returned 0 records on it. In the study of intravenous thymosin beta-4 (a different substance from TB-500, according to FDA) in healthy volunteers, adverse events were infrequent and mild or moderate, with no dose limiting toxicities or serious adverse events.18,6
Reports to FDA
FDA's BPC-157 briefing reports that its adverse event database retrieved three reports through 4 December 2025, all associated with injectable BPC-157: injection-site redness and swelling for 9 days in a woman also using injectable compounded thymosin, and shortness of breath leading to an emergency room visit with no further information.5 The third report concerned a 40-year-old woman who used a product containing BPC-157 and TB500 and developed diffuse hyperpigmentation and gingival darkening after one week of use, reproduced on rechallenge; FDA states that because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported adverse events.5 FDA states that it cannot make definitive conclusions about the safety of BPC-157 from these reports alone, and its searches of the same system returned no reports for KPV through 3 December 2025 or for TB-500 through 26 March 2025, and FDA's KPV briefing and TB-500 briefing also report no human exposure data or human data on drug products containing them.5,4,6
Safety statements about the components
FDA's safety-risk page states that compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities and that there are limited data in humans.22 A 2026 orthopaedic review states that commercial products marketed as BPC-157, thymosin beta-4 or TB-500 raise concerns regarding identity, purity, concentration, sterility and manufacturing consistency.10
Bloodwork and markers
Sources in this part
No study of the blend in the searches of PubMed on 15 November 2026 reports laboratory markers, since they returned 0 records on it. In the intravenous BPC-157 pilot study of 2 people over 2 to 3 days, the infusions resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid or blood glucose levels, and the authors state that future studies are needed to confirm the safety of intravenous BPC-157 in humans.17
Regulatory and anti-doping status
FDA states that it does not intend to issue a final determination until input from the advisory committee process has been considered and all reviews have been finalized.24
| Component | FDA | WADA 2026 Prohibited List |
|---|---|---|
| KPV4,22 | Briefing document proposes not adding KPV to the 503A Bulks List; FDA's safety-risk page lists KPV under bulk drug substances nominated but withdrawn | Not named in the text of the list |
| BPC-1575,22,23 | Briefing document proposes not adding BPC-157 to the 503A Bulks List; FDA's safety-risk page lists BPC-157 under bulk drug substances nominated but withdrawn | Named in S0, non-approved substances |
| TB-5006,22,23 | Briefing document proposes not adding TB-500 to the 503A Bulks List; FDA's safety-risk page lists the thymosin beta-4 fragment (LKKTETQ), also known as TB-500, under bulk drug substances nominated but withdrawn | Named in S2.3 as a derivative of thymosin-β4 |
| GHK-Cu22 | FDA's safety-risk page lists GHK-Cu for injectable routes of administration under bulk drug substances nominated but withdrawn | Not named in the text of the list |
FDA's page is titled as bulk drug substances for use in compounding that may present significant safety risks, with a content date of 22 April 2026.22 The WADA 2026 Prohibited List came into effect on 1 January 2026, and section S0, which names BPC-157, and section S2, which includes S2.3 naming thymosin-β4 and its derivatives such as TB-500, are each prohibited at all times, in and out of competition.23
What is not known
Sources in this part
How the four peptides behave when mixed in one vial, including absorption, clearance and tolerability, is not described in the searches of PubMed on 15 November 2026, which returned 0 records on the blend. A 2026 rat study with 8 per group reported no additional benefit of BPC-157 plus TB-500 over either alone, and 4 patients in the 2021 uncontrolled knee study received BPC 157 with thymosin beta-4 (not stated to be TB-500).21,15,10 A 2026 systematic review of GHK-Cu states that approximately 35% of the GHK-Cu primary literature in its inclusion window includes Loren Pickart or Anna Margolina (Skin Biology Inc.) as an author, that Pickart was the original isolator of the peptide and held commercial interests in the field for decades, and that this concentration of authorship limits the independence of the evidence base.11
Frequently asked questions
Sources in this part
- 4US Food and Drug Administration, 2026
- 5US Food and Drug Administration, 2026
- 6US Food and Drug Administration, 2026
- 8Mateescu et al., 2026
- 10Tham et al., 2026
- 13He et al., 2022
- 15Lee et al., 2021
- 16Lee et al., 2024
- 17Lee et al., 2025
- 21Biçer O, 2026
- 23World Anti-Doping Agency, 2026
- 24US Food and Drug Administration, 2026
What is KLOW?
KLOW is a pre-mixed vial of four peptides: KPV 10 mg, BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg, 80 mg in total. A search of PubMed on 15 November 2026 for KLOW with peptide, blend or BPC-157 in the title or summary text returned 0 records.
What is in KLOW?
KLOW contains KPV 10 mg, BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg per 80 mg vial.
Is there research on KLOW?
A search of PubMed on 15 November 2026 for KLOW with peptide, blend or BPC-157 in the title or summary text returned 0 records, and a search for all four peptides together also returned 0 records. A 2026 rat study of two of the components, BPC-157 and TB-500, reported no additional benefit of the combination over either alone.21
What is the half-life of KLOW?
The app lists about 3 hours for the blend, and no study of the blend measured it. For BPC-157 alone, a rat and dog study reported an elimination half-life of less than 30 minutes.13
Is KLOW approved?
None of FDA's three July 2026 briefing documents covers KLOW or GHK-Cu; each covers one substance (KPV, BPC-157 or TB-500), states it is not a component of an FDA-approved drug, and proposes not adding it to the 503A Bulks List.4,5,6 FDA states that it does not intend to issue a final determination until input from the advisory committee process has been considered.24
Is KLOW banned in sport?
BPC-157 is named in section S0 of the WADA 2026 Prohibited List and TB-500 in section S2.3, and both sections are prohibited at all times, in and out of competition.23 KPV and GHK-Cu are not named in the text of that list, and S0 covers any substance not addressed elsewhere on the list that has no current governmental approval for human therapeutic use, so absence from the list text does not settle the question.23
What are the side effects of KLOW?
No trial of the blend reports side effects, since a search of PubMed on 15 November 2026 returned 0 records for it. FDA's BPC-157 briefing lists three adverse event reports through 4 December 2025: injection-site redness and swelling for 9 days, shortness of breath with an emergency room visit, and hyperpigmentation and gingival darkening that recurred on rechallenge with a product containing BPC-157 and TB500.5 FDA says it cannot make definitive conclusions about the safety of BPC-157 from these reports alone.5
Do BPC-157 and TB-500 work better together?
What dose of KLOW was used in studies?
No study of KLOW is returned by a search of PubMed on 15 November 2026 for KLOW with peptide, blend or BPC-157 in the title or summary text, so there is no dose from a study of the blend. Single-component studies used, for example, 10 mg of BPC-157 injected around the inflamed area of the bladder in one procedure in 12 women, and 10 mg then 20 mg of BPC-157 by one-hour infusion in a 2-person pilot at a private clinic; both were uncontrolled.16,17,8
Guides, tools and comparisons
References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008. PMID 18061177
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026. PMID 41966639
- Tewari K, Liu TP, Im C et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med 2026. PMID 42578445
- US Food and Drug Administration. Evaluation of KPV-related bulk drug substances (KPV (free base) and KPV acetate) for inclusion on the 503A bulk drug substances list. FDA briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. FDA briefing document (KPV)
- US Food and Drug Administration. Evaluation of BPC-157-related bulk drug substances (BPC-157 (free base) and BPC-157 acetate) for inclusion on the 503A bulk drug substances list. FDA briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. FDA briefing document (BPC-157)
- US Food and Drug Administration. Evaluation of TB-500-related bulk drug substances for inclusion on the 503A bulk drug substances list. FDA briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. FDA briefing document (TB-500)
- Pawar K, Kolli CS, Rangari VK et al. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci 2017. PMID 28343991
- Mateescu DM, Gavrilescu DM, Constantinescu FE et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics 2026. PMID 42198317
- Vasireddi N, Hahamyan H, Salata MJ et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949
- Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg 2026. PMID 42937313
- Najafi N, Maatouk H, Vardanyan KG et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res 2026. PMID 42787770
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMID 26236730
- He L, Feng D, Guo H et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022. PMID 36588717
- Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl 1997. PMID 9187381
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021. PMID 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024. PMID 39325560
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PMID 40131143
- Ruff D, Crockford D, Girardi G et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010. PMID 20536472
- Miller TR, Wagner JD, Baack BR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PMID 16847171
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026. PMID 42885452
- Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg 2026. PMID 42542926
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. FDA page
- World Anti-Doping Agency. The 2026 Prohibited List. International Standard, in effect 1 January 2026. WADA 2026 Prohibited List
- US Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting, 23 to 24 July 2026 (introduction). FDA briefing document (introduction)